MGFA Scientific Session 2025

A single dose of KYV-101, a cell therapy being developed by Kyverna Therapeutics for generalized myasthenia gravis (gMG), led to rapid and sustained reductions in symptom severity — lasting up to six months thus far — in adults with gMG. That’s according to data from an interim…

Nearly one year of treatment with Remegen’s telitacicept in a clinical trial in China led to substantial and sustained reductions in symptom severity among adults with generalized myasthenia gravis (gMG). That’s according to new results from the Phase 3 trial, which were shared during the Myasthenia Gravis…

Treatment with Imaavy (nipocalimab-aahu) has led to sustained disease control for up to 1.5 years among adolescents with generalized myasthenia gravis (gMG), according to data from the long-term extension (LTE) part of a Phase 2/3 clinical trial. The study, called Vibrance-MG (NCT05265273), is now evaluating Imaavy’s safety…

Weekly treatment with gefurulimab —an investigational C5 inhibitor from Alexion, Astrazeneca Rare Disease, that’s designed to be self-administered — led to early and sustained reductions in disease severity for adults with generalized myasthenia gravis (gMG), according to top-line data from a Phase 3 clinical trial. The findings…

Vyvgart (efgartigimod alfa-fcab) led to significant and clinically meaningful reductions in disease severity among adults with generalized myasthenia gravis (gMG) who test negative for disease-causing antibodies targeting the acetylcholine receptor (AChR). Notably, benefits were seen across different subgroups of anti-AChR antibody-negative patients, who are also known as having…

Vyvgart (efgartigimod alfa-fcab), currently approved in the U.S. for treating certain adults with generalized myasthenia gravis (gMG), safely eased disease severity in adolescents with the disease, according to new data from a Phase 2/3 trial. Called ADAPT JR (NCT04833894), the study is still recruiting younger children,…